摘要
Cancers are heterogeneous at the cellular level.Cancer stem cells/tumor initiating cells(CSC/TIC)both initiate tumorigenesis and are responsible for therapeutic resistance and disease relapse.Elimination of CSC/TIC should therefore be able to reverse therapy resistance.In principle,this could be accomplished by either targeting cancer stem cell surface markers or“stemness”pathways.Although the successful therapeutic elimination of“cancer stemness”is a critical goal,it is complex in that it should be achieved without depletion of or increases in somatic mutations in normal tissue stem cell populations.In this perspective,we will discuss the prospects for this goal via pharmacologically targeting differential Kat3 coactivator/Catenin usage,a fundamental transcriptional control mechanism in stem cell biology.
基金
Kahn M has been supported by NIH P30CA014089,R01CA166161,R21NS074392,R21AI105057,and R01HL112638
Bild A has been supported by NIH U54CA209978.
